Stockscreener 앱 받기
7.35
0.81%
-0.06
시간 외 거래:
29.72
22.37
+304.35%
전일 마감가:
$7.41
열려 있는:
$7.49
하루 거래량:
719.36K
Relative Volume:
0.42
시가총액:
$770.93M
수익:
-
순이익/손실:
$-57.39M
주가수익비율:
-5.0007
EPS:
-1.4698
순현금흐름:
$-45.79M
1주 성능:
+1.52%
1개월 성능:
+5.15%
6개월 성능:
+192.83%
1년 성능:
+1,818%
1일 변동 폭
$7.175
$7.63
1주일 범위
$7.085
$7.805
52주 변동 폭
$0.3233
$7.94
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, GOODO, SHMD, PSNYW, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.485 | 3.18B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.29 | 306.92M | 52.15M | -21.46M | 0 | -0.4675 |
PSNYW
Polestar Automotive Holding Uk
|
3.09 | 271.04M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.06 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 개시 | Piper Sandler | Overweight |
| 2026-01-23 | 재개 | Leerink Partners | Outperform |
| 2025-12-22 | 개시 | Jefferies | Buy |
| 2025-11-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - Investing News Network
Bladder cancer drug NDV-01 heads to AUA with Phase 3 on track - Stock Titan
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - GlobeNewswire Inc.
Commodore holds 5.5M RLMD shares, including 4.21M warrant shares (RLMD) - Stock Titan
Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect? - MSN
Relmada Therapeutics (RLMD) Stock Chart | Relmada Therapeutics Inc. posts 103% EPS miss vs estimatesReal Trader Network - UBND thành phố Hải Phòng
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect? - qz.com
Relmada Therapeutics Inc erwartet einen Verlust von 70 Cents pro AktieEarnings Preview - TradingView
Relmada Therapeutics (RLMD) Stock: Solid Choice? (Breakout Watch) 2026-04-20Investment Picks - Xã Châu Thành
Relmada (NASDAQ: RLMD) details 2025 turnaround, seeks share and plan increases - Stock Titan
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3%Here's What Happened - MarketBeat
Relmada Therapeutics shares jump 25% after promising bladder cancer trial results - MSN
Q3 2025 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Relmada Therapeutics (RLMD) price target increased by 59.26% to 14.62 - MSN
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat
Form PRE 14AOther preliminary proxy statements - ADVFN
[EFFECT] RELMADA THERAPEUTICS, INC. SEC Filing - Stock Titan
Shorts Report: Is Relmada Therapeutics Inc a speculative investmentGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale under 424B3 - Stock Titan
Relmada Therapeutics (NASDAQ:RLMD) Hits New 12-Month HighShould You Buy? - MarketBeat
Aug Update: Should I invest in Relmada Therapeutics Inc before earningsM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
Volume Recap: Does Relmada Therapeutics Inc offer margin of safety2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Report: Whats next for Relmada Therapeutics Inc stock2026 WrapUp & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Mizuho reiterates Relmada stock rating on Phase 3 trial progress By Investing.com - Investing.com Australia
Mizuho reiterates Relmada stock rating on Phase 3 trial progress - Investing.com UK
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider
Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD) - The Globe and Mail
Relmada (NASDAQ: RLMD) raises $100M, adds NDV-01 and sepranolone - Stock Titan
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
Can Relmada Therapeutics (RLMD) Stock Go Higher | Price at $6.94, Down 0.72%Investment Signal Network - Cổng thông tin điện tử Tỉnh Sơn La
RLMD SEC FilingsRelmada Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RLMD PE Ratio & Valuation, Is RLMD Overvalued - Intellectia AI
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement - Stock Titan
RLMD Stock Analysis: Relmada Therapeutics Inc slips 1.55% to $6.99 in biotech trading - UBND thành phố Hải Phòng
Relmada Therapeutics Inc. (US75955J4022.SG) analyst ratings, estimates and forecasts - Yahoo Finance UK
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength - The Globe and Mail
RLMD Stock Surges 42% in a Week: Here's What You Should Know - Eastern Progress
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha
With 20-plus years in drug development, Raj Pruthi joins PreveCeutical - Stock Titan
Relmada wins bullish view at Piper Sandler on cancer therapy - MSN
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):